NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease

被引:88
作者
Asada, Ayumi [1 ]
Nishida, Atsushi [1 ]
Shioya, Makoto [1 ]
Imaeda, Hirotsugu [1 ]
Inatomi, Osamu [1 ]
Bamba, Shigeki [1 ]
Kito, Katsuyuki [1 ]
Sugimoto, Mitsushige [1 ]
Andoh, Akira [1 ]
机构
[1] Shiga Univ Med Sci, Dept Med, Otsu, Shiga 5202192, Japan
关键词
NUDT15; IBD; Azathioprine; 6-Mercaptopurine; INOSINE TRIPHOSPHATE PYROPHOSPHATASE; S-METHYLTRANSFERASE GENOTYPES; ADVERSE DRUG-REACTIONS; AZATHIOPRINE THERAPY; POLYMORPHISM; MERCAPTOPURINE; INTOLERANCE; TOXICITY; VARIANT; RISK;
D O I
10.1007/s00535-015-1142-4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
NUDT15 R139C (rs116855232) is a recently identified genetic factor responsible for thiopurine-induced leukocytopenia and hair loss. In this study, we investigated the association of NUDT15 R139C with 6-thioguanine nucleotide (6-TGN) levels and thiopurine-induced leukocytopenia in Japanese patients with inflammatory bowel disease (IBD). Two hundred and sixty-four subjects (103 healthy volunteers and 161 IBD patients treated with thiopurines) were enrolled. Genotyping for NUDT15 R139C was performed using Custom TaqMan(A (R)) SNP genotyping assays. The NUDT15 C/C, C/T, and T/T genotypes were 80.7, 18.2, and 1.1 %, respectively. The allelic frequency was 10.2 %. Among 161 IBD patients, there was no significant difference in 6-TGN levels among the NUDT15 genotypes. Forty-five patients (27.9 %) developed leukocytopenia (WBC < 3000/mu l), and the C/T and T/T genotypes were significantly associated with the development of leukocytopenia (P = 1.7 x 10(-5)). In these patients, 6-TGN levels were not significantly different between NUDT15 genotypes. NUDT15 R139C was significantly associated with early (< 8 weeks) (P = 1.03 x 10(-4)) and late (> 8 weeks) leukocytopenia (P = 4.3 x 10(-4)). The decrease in WBC count at 2 and 4 weeks was significantly higher in patients with the C/T or T/T genotypes as compared to the patients with the C/C genotype. All patients with the T/T genotype (n = 2) developed early severe hair loss and severe leukocytopenia (< 1000/mu l). The logistic regression analysis revealed that NUDT15 R139C was the sole genetic factor responsible for the thiopurine-induced leukocytopenia (P = 0.001). These results suggest that NUDT15 R139C-related thiopurine-induced leukocytopenia is mediated by a 6-TGN-independent mechanism.
引用
收藏
页码:22 / 29
页数:8
相关论文
共 33 条
[1]   ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression [J].
Allorge, D ;
Hamdan, R ;
Broly, F ;
Libersa, C ;
Colombel, JF .
GUT, 2005, 54 (04) :565-565
[2]   Update 2014: Advances to Optimize 6-Mercaptopurine and Azathioprine to Reduce Toxicity and Improve Efficacy in the Management of IBD [J].
Amin, Jaimin ;
Huang, Brian ;
Yoon, Jessica ;
Shih, David Q. .
INFLAMMATORY BOWEL DISEASES, 2015, 21 (02) :445-452
[3]   The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease [J].
Ban, Hiromistu ;
Andoh, Akira ;
Imaeda, Hirotsugu ;
Kobori, Ayako ;
Bamba, Shigeki ;
Tsujikawa, Tomoyuki ;
Sasaki, Masaya ;
Saito, Yasuharu ;
Fujiyama, Yoshihide .
JOURNAL OF GASTROENTEROLOGY, 2010, 45 (10) :1014-1021
[4]   Analysis of Thiopurine S-Methyltransferase Genotypes in Japanese Patients with Inflammatory Bowel Disease [J].
Ban, Hiromitsu ;
Andoh, Akira ;
Tanaka, Aiko ;
Tsujikawa, Tomoyuki ;
Sasaki, Masaya ;
Saito, Yasuharu ;
Fujiyama, Yoshihide .
INTERNAL MEDICINE, 2008, 47 (19) :1645-1648
[5]   Assessment of Thiopurine S-Methyltransferase Activity in Patients Prescribed Thiopurines: A Systematic Review [J].
Booth, Ronald A. ;
Ansari, Mohammed T. ;
Loit, Evelin ;
Tricco, Andrea C. ;
Weeks, Laura ;
Doucette, Steve ;
Skidmore, Becky ;
Sears, Margaret ;
Sy, Richmond ;
Karsh, Jacob .
ANNALS OF INTERNAL MEDICINE, 2011, 154 (12) :814-823
[6]   Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease [J].
Derijks, LJJ ;
Gilissen, LPL ;
Engels, LGJB ;
Bos, LP ;
Bus, PJ ;
Lohman, JJHM ;
van Deventer, SJH ;
Hommes, DW ;
Hooymans, PM .
THERAPEUTIC DRUG MONITORING, 2006, 28 (01) :45-50
[7]   Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease [J].
Gearry, RB ;
Barclay, ML ;
Burt, MJ ;
Collett, JA ;
Chapman, BA .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2004, 13 (08) :563-567
[8]   Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: A review [J].
Gisbert, Javier P. ;
Gomollon, Fernando .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (07) :1783-1800
[9]   IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations [J].
Haglund, Sofie ;
Taipalensuu, Jan ;
Peterson, Curt ;
Almer, Sven .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (01) :69-77
[10]   Genetic analysis of thiopurine methyltransferase polymorphism in a Japanese population [J].
Hiratsuka, M ;
Inoue, T ;
Omori, F ;
Agatsuma, Y ;
Mizugaki, M .
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2000, 448 (01) :91-95